Bausch Health Expands Fraxel FTX Skin Resurfacing Tech to Australia
Event summary
- Bausch Health's Solta Medical launched Fraxel FTX in Australia on September 1, 2026.
- Fraxel FTX is the next-generation skin resurfacing technology with dual wavelengths for targeted treatment.
- The system features precision treatment delivery, intelligent optical tracking, and an ergonomic handpiece.
- Solta Medical provides clinical education and business support to Australian healthcare practitioners.
The big picture
Bausch Health's expansion of Fraxel FTX into Australia underscores its strategic focus on the aesthetics market. The launch builds on the company's 20-year heritage in skin resurfacing technology, aiming to support modern aesthetic practices with enhanced precision and patient comfort. This move aligns with broader industry trends toward advanced dermatological solutions and highlights Bausch Health's commitment to innovation in the healthcare sector.
What we're watching
- Market Penetration
- How quickly Fraxel FTX will gain adoption among Australian healthcare practitioners.
- Competitive Positioning
- Whether Bausch Health can sustain its leadership in the aesthetics market with this technology.
- Regulatory Compliance
- The pace at which regulatory approvals for similar technologies will be granted in other regions.